Chugai’s advanced non-small cell lung cancer drug approved in Taiwan

Japan’s Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced that Chugai Pharma Taiwan Ltd., a wholly owned subsidiary of Chugai, obtained approval from the TFDA for the anti-cancer agent, alectinib hydrochloride (brand name: Alecensa®) for the treatment of people with “anaplastic lymphoma kinase (ALK) positive, advanced non-small cell lung cancer (NSCLC) who have progressed on or those intolerant to crizotinib.”

Read more